Literature DB >> 30586159

Pevonedistat, a Neuronal Precursor Cell-Expressed Developmentally Down-Regulated Protein 8-Activating Enzyme Inhibitor, Is a Potent Inhibitor of Hepatitis B Virus.

Kazuma Sekiba1, Motoyuki Otsuka1, Motoko Ohno1, Mari Yamagami1, Takahiro Kishikawa1, Takahiro Seimiya1, Tatsunori Suzuki1, Eri Tanaka1, Rei Ishibashi1, Kazuyoshi Funato1, Kazuhiko Koike1.   

Abstract

Hepatitis B virus (HBV) infection is a major health concern worldwide. To prevent HBV-related mortality, elimination of viral proteins is considered the ultimate goal of HBV treatment; however, currently available nucleos(t)ide analogs rarely achieve this goal, as viral transcription from episomal viral covalently closed circular DNA (cccDNA) is not prevented. HBV regulatory protein X was recently found to target the protein structural maintenance of chromosomes 5/6 (Smc5/6) for ubiquitination and degradation by DDB1-CUL4-ROC1 E3 ligase, resulting in enhanced viral transcription from cccDNA. This ubiquitin-dependent proteasomal pathway requires an additional ubiquitin-like protein for activation, neuronal precursor cell-expressed developmentally down-regulated protein 8 (NEDD8). Here, we show that pevonedistat, a NEDD8-activating enzyme inhibitor, works efficiently as an antiviral agent. Pevonedistat significantly restored Smc5/6 protein levels and suppressed viral transcription and protein production in the HBV minicircle system in in vitro HBV replication models and in human primary hepatocytes infected naturally with HBV.
Conclusion: These results indicate that pevonedistat is a promising compound to treat chronic HBV infection.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30586159     DOI: 10.1002/hep.30491

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

Review 1.  Hepatitis B: Current Status of Therapy and Future Therapies.

Authors:  Elias Spyrou; Coleman I Smith; Marc G Ghany
Journal:  Gastroenterol Clin North Am       Date:  2020-03-29       Impact factor: 3.806

Review 2.  Mapping the Interactions of HBV cccDNA with Host Factors.

Authors:  Nur K Mohd-Ismail; Zijie Lim; Jayantha Gunaratne; Yee-Joo Tan
Journal:  Int J Mol Sci       Date:  2019-09-01       Impact factor: 5.923

Review 3.  Hepatitis B virus-host interactions and novel targets for viral cure.

Authors:  Gaëtan Ligat; Eloi R Verrier; Michael Nassal; Thomas F Baumert
Journal:  Curr Opin Virol       Date:  2021-05-22       Impact factor: 7.121

4.  Hepatitis B Virus HBx Protein Mediates the Degradation of Host Restriction Factors through the Cullin 4 DDB1 E3 Ubiquitin Ligase Complex.

Authors:  Marissa M Minor; F Blaine Hollinger; Adrienne L McNees; Sung Yun Jung; Antrix Jain; Joseph M Hyser; Karl-Dimiter Bissig; Betty L Slagle
Journal:  Cells       Date:  2020-03-30       Impact factor: 6.600

Review 5.  Targeting the Host for New Therapeutic Perspectives in Hepatitis D.

Authors:  Vincent Turon-Lagot; Antonio Saviano; Catherine Schuster; Thomas F Baumert; Eloi R Verrier
Journal:  J Clin Med       Date:  2020-01-14       Impact factor: 4.241

Review 6.  Neddylation: A Versatile Pathway Takes on Chronic Liver Diseases.

Authors:  Jiping Yao; Xue Liang; Yanning Liu; Min Zheng
Journal:  Front Med (Lausanne)       Date:  2020-10-19

7.  The fatty-acid amide hydrolase inhibitor URB597 inhibits MICA/B shedding.

Authors:  Kazuma Sekiba; Motoyuki Otsuka; Takahiro Seimiya; Eri Tanaka; Kazuyoshi Funato; Yu Miyakawa; Kazuhiko Koike
Journal:  Sci Rep       Date:  2020-09-23       Impact factor: 4.379

8.  Neddylation inhibitor MLN4924 has anti-HBV activity via modulating the ERK-HNF1α-C/EBPα-HNF4α axis.

Authors:  Mingjie Xie; Huiting Guo; Guohua Lou; Jiping Yao; Yanning Liu; Yi Sun; Zhenggang Yang; Min Zheng
Journal:  J Cell Mol Med       Date:  2020-12-02       Impact factor: 5.295

9.  Humanized virus-suppressing factor inhibits hepatitis B virus infection by targeting viral cell entry.

Authors:  Yu Miyakawa; Motoyuki Otsuka; Kazuma Sekiba; Kazuyoshi Funato; Kazuhiko Koike
Journal:  Heliyon       Date:  2021-07-14

Review 10.  Novel Therapies of Hepatitis B and D.

Authors:  Iman Waheed Khan; Mati Ullah Dad Ullah; Mina Choudhry; Mukarram Jamat Ali; Muhammad Ashar Ali; Sam L K Lam; Pir Ahmad Shah; Satinder Pal Kaur; Daryl T Y Lau
Journal:  Microorganisms       Date:  2021-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.